perillyl alcohol has been researched along with Angiogenesis, Pathologic in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Athar, M; Chatman, L; Dent, P; Fisher, PB; Lebedeva, IV; Sarkar, D; Su, ZZ; Vozhilla, N | 1 |
Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T | 1 |
Ripple, GH; Wilding, G | 1 |
1 review(s) available for perillyl alcohol and Angiogenesis, Pathologic
Article | Year |
---|---|
Drug development in prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Cell Cycle; Cell Differentiation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Flavonoids; Humans; Male; Monoterpenes; Neoplasm Metastasis; Neovascularization, Pathologic; Piperidines; Prostatic Neoplasms; Signal Transduction; Survival Rate; Terpenes; Vitamin D | 1999 |
2 other study(ies) available for perillyl alcohol and Angiogenesis, Pathologic
Article | Year |
---|---|
Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemoprevention; Combined Modality Therapy; Disease Models, Animal; Genetic Therapy; Humans; Interleukins; Mice; Mice, Nude; Monoterpenes; Neovascularization, Pathologic; Pancreatic Neoplasms; Survival Analysis; Xenograft Model Antitumor Assays | 2008 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytokines; Dacarbazine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glioma; Humans; Mice; Monoterpenes; Nelfinavir; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Temozolomide; Xenograft Model Antitumor Assays | 2012 |